SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
FDA
Cell and Gene Therapy Sector Enters ‘Critical’ Period After Marks’ FDA Exit
As tariffs, HHS workforce cuts and the ouster of CBER Director Peter Marks threaten the “lifeblood” of the cell and gene therapy space, experts express wariness over the unknowns and optimism that Marks’ legacy will carry on.
April 28, 2025
 · 
7 min read
 · 
Heather McKenzie
Contemporary art collage. Creative design. Illusion hand cutting rope that man climbing up. Professional challenges and competition. Concept of business, creativity, surrealism, growth, motivation
Layoffs
Caribou Changes Course Again, Lays Off 32% of Workforce
The cell and gene therapy company is cutting 47 employees and its entire lupus program to focus resources on two CAR Ts. The move follows a reconfiguration last year to move into immunology.
April 25, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
screenshot of Marty Makary speaking on the Megyn Kelly Show
FDA
Fact or Fiction? Unpacking FDA Commissioner Marty Makary’s First Interviews
As Marty Makary nears the end of his first month on the job, the FDA Commissioner sat down for two interviews, offering statements that alternatively contradict and jibe with reported events.
April 25, 2025
 · 
7 min read
 · 
Heather McKenzie
House on heap of money. Property tax. Construction cost. Payment of rent, loan, mortgage. Investing in real estate. Purchase, sale of housing. Building development concept. 3d render
Earnings
AbbVie Criticizes Trump’s Drug Pricing Proposal, Deflects Tariff Concerns
While AbbVie handily beat expectations this quarter, the company faces declining Humira sales and a challenged aesthetics business, plus the same macro headwinds blowing against the entire industry.
April 25, 2025
 · 
3 min read
 · 
Annalee Armstrong
Stagflation, economic slow down or recession while inflation high up, GDP growth decrease causing by unemployment concept, fearful businessman riding fall down economic graph with inflation high up.
Immunology and inflammation
Vyne Crashes After Safety Signal in Dogs Puts Hold on Clinical Trial of Plaque Psoriasis
The hold, placed by the FDA on an early-stage clinical trial of an experimental BET inhibitor, stems from a recent observation of testicular toxicity in canines given the treatment.
April 25, 2025
 · 
2 min read
 · 
Tristan Manalac
Creative photo collage or modern art collage featuring symbols of law and justice. Hand holding a gavel and scales of justice with books about law.
Legal
Judge Rules Against Semaglutide Compounders After Shortage Declared Over
Big compounders will have until May 22 to stop producing and dispensing compounded semaglutide, while smaller, state-run pharmacies must immediately stop making copies of the blockbuster drug.
April 25, 2025
 · 
2 min read
 · 
Tristan Manalac
Gilead's headquarters in Silicon Valley
Earnings
Gilead’s PrEP Launch Full Speed Ahead Despite Macro Pressures on HIV Space
Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch remain on track.
April 25, 2025
 · 
3 min read
 · 
Tristan Manalac
View of Chicago Skyline from North Avenue Beach
Cancer
Merck, Boehringer Ingelheim, More To Present Key Data at AACR ’25
Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment landscape for head and neck and lung cancer, and implications for specific drug modalities like TIGIT and VEGF.
April 25, 2025
 · 
4 min read
 · 
Tristan Manalac
White arrow on circle wooden move on different direction with black arrow on cube for business and technology disruption concept.
Earnings
BMS Reports Mixed Earnings as Growth Portfolio Makes Up for Generic Pressure
Despite a dip in sales and a recent schizophrenia stumble, the company drew an optimistic outlook for sales for the rest of the year, even as the specter of pharmaceutical tariffs looms.
April 24, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS